The latest advice for managing patients with type 2 diabetes who also have established cardiovascular disease is that sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists should be considered. However, the importance of achieving appropriate glycaemic targets remains.
